Optomed Plc: Half-year report January – June 2026

Optomed reported Q2 revenue of EUR 3.5m, down 8.6% y/y (currency-adjusted: -7.3%). Devices segment revenue fell 18.4% to EUR 1.2m (currency-adjusted: -15.0%), though recurring Devices revenue continued rising, supported by Aurora AEYE deployments in the US and Optomed Lumo software services.

Analysis

The key mechanism is not the top-line decline itself, but the mix shift it implies. If hardware demand is soft while recurring software/service revenue is still climbing, the business is trying to re-rate from cyclical device sales to annuity-like revenue — but at this revenue base, that only helps if it also improves gross margin and fixed-cost absorption. Otherwise, the market will treat the recurring stream as a cushion, not a catalyst.

The second-order risk is channel health: device weakness can signal slower installed-base expansion, which eventually limits the conversion funnel for software deployments. That matters because the software narrative is only durable if the company keeps seeding new accounts; if procurement is being delayed or customers are testing competing workflows, the recurring line can decelerate with a lag. Larger ophthalmic imaging vendors and integrated workflow players are positioned to use bundle pricing and financing to defend share if this softness persists.

Near term, the stock’s reaction should be driven by whether the next update shows recurring revenue accelerating enough to offset device erosion. Over 1-3 months, any rerating is contingent on evidence of margin inflection, not just deployment anecdotes. The contrarian view is that consensus may be over-penalizing the hardware slide and underestimating a software pivot, but that case only works if cash conversion and churn data confirm the pivot over 6-18 months.

Key Decisions for Investors

• For accounts with Nordic small-cap access, use any post-print strength to reduce or sell Optomed on the thesis that device weakness is still outrunning annuity growth; risk/reward remains negative until recurring revenue proves it can cover the fixed cost base over 2 consecutive quarters.
• No broad-sector short in IHI/XLV: this is too idiosyncratic to justify medtech beta exposure. Treat it as a single-name operating execution issue, not a read-through for the whole healthcare equipment complex.
• Set a 1-2 quarter watch item on recurring revenue growth and gross margin expansion. If recurring revenue does not materially outgrow device decline by the next report, consider exiting any residual exposure; if it does, the thesis flips toward a software-enabled re-rating.
• If a liquid local peer or basket becomes available, prefer a relative-value long in integrated ophthalmology/imaging platforms against Optomed only if they can monetize installed base faster; otherwise stay flat and avoid forced expressions.